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SECRETARIAT  OF  THE  COMMISSION  OF 
THE  EUROPEAN  ECONOMIC  COMMUNITY beginning of the fourth year reckoned from 
the  end of the year of notification  of this 
directive,  by a  non-cumulative  system,  un-
der which tax will  normally be imposed on 
goods  and  services  at  only  one  stage. 
Member  States  will,  however,  remain  free 
to  fix  independently  a  supplementary  tax 
at  the  retail  stage  superimposed  upon  the 
above-mentioned  non-cumulative  tax,  or, 
if  they  have  elected  to  apply  an  added-
value  tax  system,  to extend  this  system  to 
cover  retail  trade. 
As  from  the  end  of  the  above-mentioned 
period,  standard-rate  compensatory  meas-
ures  for  imports  and exports  shall  no lon-
ger be permitted in trade between Member 
States. 
Article 2 
The Member States  shall inform the  Com-
mission  at  the  end  of  each  year  of  the 
period  mentioned  in  Article  1  of  any 
measures  taken  or  contemplated  to  fulfil 
the  obligation  laid  down  in  the  said 
Article. 
Article 3 
The  Member  States  shall  introduce,  at 
latest  by  the  end  of  the  transition  period, 
a  common  system  of added-value  taxation 
embracing  all  stages  up  to  and  including 
wholesale  trade.  The  form  of  this  tax 
system  and  the  methods  of  applying  it 
shall  be  decided  by  the  Council,  acting  on 
proposals  of  the  Commission,  before  the 
end of the period  referred  to in Article  1. 
The  Member  States  will  be  free  to  apply 
independently  a  supplementary  tax  on  re-
tail  sales,  or  to make  the  common  added-
value  tax applicable  to  this  stage  also. 
Article 4 
The Commission will  study by  what means 
and  within  what  period  of  time  the  har-
monization  of turnover  taxes  provided  for 
in  Article  3  shaH  attain  its  final  object, 
namely  the  abolition  of  countervailing 
charges  on  imports  and  drawbacks  on 
exports  in  trade  between  Member  States, 
the  neutral  effect·  of  turnover  taxes  on 
trade  being  safeguarded.  The  Commission 
will  submit its  proposals  to the  Council  in 
sufficient  time  for  the  latter  to take  deci-
sions  before  the  end  of  the  transition 
period. 
Article  5 
The  present  directive  is  addressed  to  all 
Member  States. 
Draft  Council  directive  on  the  harmonization  of  laws  and  regulations 
governing  pharmaceutical  products 
(Proposal  submitted  by  the  Commission  to  the  Council  on  5  November  1962) 
The  Council  of  the  European  Economic 
Community, 
Having  regard  to  the  provisions  of  the 
Treaty  and  in  particular  Article  100 
thereof; 
Having regard  to the proposal of the  Com-
mission; 
Having  regard  to  the  opinion of the Euro-
pean  Parliament; 
Having  regard  to  the  opinion  of the  Eco-
nomic  and  Social  Committee; 
Whereas  the  main  purpose  of  legislation 
on  the  production  and  distribution  of 
branded  pharmaceutical  must  be  to  safe-
guard  public  health; 
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Whereas,  however,  this  object  must  be 
attained  by  means  that  do  not hinder  the 
development  of  the  pharmaceutical  indus-
try  and  trade  in  its  products  within  the 
Community; 
Whereas  certain  national  arrangements 
constitute  obstacles  to  trade in  pharmaceu-
tical  products  within  the  Community  and 
therefore  directly  affect  the  establishment 
and  functioning  of  the  Common  Market; 
Whereas  these  obstacles  must be overcome 
by  harmonization  of  legislation  on  phar-
maceutical  matters  in  general; 
Whereas,  however,  such  harmonization  of 
legislation  can  only  be  brought  about 
gradually,  priority  being  given  to  those disparities which may most affect the func-
tioning  of the  Common  Market, 
Has  adopted  the  present  directive : 
CHAPTER I 
Definitions  and  field  of  application 
Article  1 
For the  purposes  of  the  present  directive, 
the  following  definitions  shall  apply : 
1.  Branded  pharmaceuticals 
Any  medical  preparation  sold  under  a 
special  name  and put up  in  a  special  way. 
2.  M e d i c a 1  p r e p a r a t i o n 
Any  substance  or  mixture  which  is 
claimed  to  cure  or  prevent  disease  in 
human  beings  (or  animals). 
The term includes any substance or mixture 
administered  to human beings  (or animals) 
for  purposes  of  diagnosis  or  in  order  to 
restore,  improve or influence organic func-
tions. 
For  purposes  of  health  control,  medical 
preparations are deemed to include surgical 
sutures,  sterile  dressings  and  materials 
which,  for  the  purposes  referred  to  in  the 
foregoing  paragraph,  are  permanently  or 
temporarily  introduced into the  human  (or 
animal)  organism. 
3.  Sub stance 
Any  matter,  be  it of : 
human  origin,  such  as  human  blood  and 
blood  derivatives; 
animal  origin,  such  as  micro-organisms, 
whole  animals,  parts  of  organs,  microbial 
or animal secretions, toxins,  extracts, blood 
derivatives,  etc. 
vegetable  origin,  such  as  micro-organisms, 
plants, parts of plants, vegetable secretions, 
extracts,  etc. 
chemical  origin,  such  as  natural  elements 
and  chemicals  and  compounds  produced 
by  chemical  processes. 
Article  2 
The  provrs10ns  of  Chapters  III  to  V  of 
the  present  directive  shall  apply  only  to 
branded  pharmaceuticals  for  human  use 
intended  for  sale  in  the  Member States. 
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CHAPTER  II 
Licensing  of  branded  pharmaceuticals 
Article  3 
No branded pharmaceutical may be offered 
for  sale  in  the  member  countries  except 
under  licence  issued  by  the  competent 
authority  in  the  said  countries. 
Article 4 
The  licence  referred  to  in  Article  3  shall 
be  withheld  if,  on the basis  of the partic-
ulars  and  supporting  documents  listed  in 
Article 6,  the  branded pharmaceutical does 
not  have  the  therapeutic  potency  claimed 
for it or if such potency is  not adequately 
substantiated  by  the  applicant,  or  if  the 
nature and quantities of the ingredients are 
not stated.  The licence shall  also be with-
held  if  the  data  and  documents  submitted 
in  support  of  the  application  are  not  in 
conformity with the provisions of Article 6. 
Article 5 
The  competent  authorities  of the  Member 
States  may  refuse  to  license  the  sale  of a 
branded  pharmaceutical  for  use  as  a 
contraceptive  if  under  their  legislation  the 
sale  of pharmaceuticals intended. essentially 
for  such  purposes  is  prohibited. 
Article 6 
The  licence  referred  to  in  Article  3  shall 
be  issued  by  the  competent  authority  of 
the  Member  States  on  application  by  the 
manufacturer  and,  where  appropriate,  the 
distributor. 
The  application  must  be  accompanied  by 
the  following  particulars  and  supporting 
documents: 
1.  Name  or  registered  trading  name  and 
address  of  the  manufacturer,  and,  where 
appropriate,  name  or  registered  trading 
name  and  address  of  the  distributor. 
2.  Trade  name  of the  preparation  (brand 
name, or usual description accompanied by 
brand name  or by name  of manufacturer, 
or  scientific  description  accompanied  by 
brand name or by name  of manufacturer). 
3.  Nature and quantities of ingredients,  as 
usually  described,  without  empirical  che-
mical  formulae,  and  internationally  re-
cognized  common  name  as  recommended 
by  the  World  Health  Organization. 
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4.  Short  description  of  method  of  pre-
paration. 
5.  Therapeutical  indications,  contra-indica-
tions  and secondary  effects. 
6.  Formulation, directions for use,  dosage; 
indications  as  to  stability. 
7.  Tests  applied  (qualitative  and  quantita-
tive  analysis  of  ingredients  and  finished 
product;  special  tests,  e.g.  for  sterility, 
pyrogenic  property, presence  of heavy  me-
tals,  stability;  biological  tests  and  tests  for 
toxicity). 
8.  Results  of  physio-chemical,  biological 
or  micro-biological,  pharmacological,  toxi-
cological  and clinical  tests. 
9.  One  or  more  samples  or  dummies  of 
the  product  as  proposed  to  be  offered  for 
sale,  together  with  accompanying  prospec-
tus  if  any. 
10.  For  foreign  products:  licence  issued 
for sale in the country of origin or another 
country. 
11.  Document  attesting  that  the  manufac-
turer  holds  a  licence  in  his  own  country 
to  produce  pharmaceuticals. 
Article  7 
The  Member  States  shall  make  arrange-
ments  for  the  licensing  procedure  to  take 
place  within  the  following  time-limits : 
1.  30  days  from  the  date  of  submission 
for  the  decision  as  to  whether,  having 
regard  to  the  terms  of  Article  6,  the  ap-
plication  can  be  entertained; 
2.  90  days  from  the  date  of the  decision 
provided  for  in  paragraph  1  for  the  deci-
sion  to  grant or withhold  the  licence  hav-
ing  regard  to the  terms  of Article  4. 
In  exceptional  cases,  the  time-limit  pres-
cribed in paragraph 2  may be extended for 
a  further  90  days.  The applicant shall  be 
notified  to  this  effect  before  the  expiry 
of  the  initial  time-limit. 
Article 8 
The  Member  States  shall  take  steps  to 
enable  the  applicant  to  furnish  proof  that 
the  tests  on the finished  product described 
by him as  required by Article  6  have been 
made. 
Article  9 
The  licence  granted  under  Article  3  shall 
not impair the liability under ordinary law 
of the  manufacturer  or  where  appropriate 
the distributor. 
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Article  10 
The  licence  shall  be  valid  for  five  years 
and shall be renewable for five-year periods 
at  the  request  of  the  licensee  submitted 
three  months  before  the  end  of  any  such 
period. 
CHAPTER III 
Suspension  or  withdrawal  of  licence 
Article  11 
The competent authorities of the Member 
States shall suspend or withdraw the licence 
to  sell  a  branded  pharmaceutical  if  the 
latter appears  to be  harmful  under normal 
conditions  of use,  if it  does  not  have  the 
therapeutic potency claimed for it or if the 
nature  and  quantities  of its  ingredients  are 
not in conformity with  the  statement made 
in accordance with  Article  6,  paragraph  3. 
The  licence  shall  also  be  suspended  or 
withdrawn  if  the  particulars  supplied  in 
the  supporting  documents  submitted  pur-
suant  to Article  6  are  found  to be  incor-
rect or if the  tests  on the finished  product 
stipulated in Article 8 have not been made. 
Article  12 
Any  decision  taken  under  Articles  4,  5 
and 11  shall state the precise grounds there-
for.  The  person  concerned  shall  be  noti-
fied  thereof  and  at  the  same  time  be  in-
formed of the remedies open to him at law 
and  of  the  time-limit  within  which  an 
appeal  may  be  lodged. 
CHAPTER IV 
Labelling 
Article  13 
The  containers  and  outer  packing  of 
branded  pharmaceuticals  must  bear  the 
following  particulars : 
1.  Name  of  the  product,  which  may  be 
either  a  brand  name  or  the  usual  descrip-
tion  accompanied  by  a  brand name  or by 
the  name of the manufacturer, or a  scien-
tific  description  accompanied  by  a  brand 
name or by the name of the manufacturer. 
If the  product  bears  a  brand  name  and 
consists  of  a  single  active  substance  with 
a  common  international  name  recom-mended by the World Health Organization, 
such  name  shaH  appear  in  bold  lettering 
underneath  the  brand  name. 
2.  Nature  and  quantities  of  the  active 
principles  and  the  quantity  of  each  per 
unit  or expressed  in percentages  according 
to  the  formulation. 
If any  of the  active  principles  has  a  com-
mon  international  name  recommended  by 
the  WHO,  this  name  must  also  be  used. 
3.  Reference  number  for  identification 
(batch  number). 
4.  Licence  number. 
5.  Name and 11ddress  of the  manufacturer 
or,  where  appropriate,  the  distributor. 
6.  Method  of  administration. 
7.  Latest  date  for  use  in the  case  of pro-
ducts with a  period of stability of less  than 
three  years. 
8.  Special  storage  precautions  where  ap-
propriate. 
The  formulation  and the  contents  must  be 
stated  on  the  outer packing. 
Article  14 
For products put up  in  ampoules,  the par-
ticulars  mentioned  in  the  first  paragraph 
of  the  foregoing  article  are  to  be  given 
on  the  outer packing.  On  the  containers, 
however,  only  the  following  particulars 
need  be  given : 
i)  name  of the  product; 
ii)  quantities  of  the  active  principles; 
iii) method  of  administration; 
iv)  latest  date  for  use. 
Article  15 
As  regards  small  containers  other  than 
ampoules,  holding  only  one  dose  and  on 
which it is  impossible to give the particulars 
referred to in Article  14,  the provisions  of 
Article 13  shall  apply to the outer packing 
only. 
Article  16 
In the  case  of narcotics,  the  outer packing 
and  the  container  must  bear  in  addition 
to  the  particulars  stipulated  in  Article  13 
a  special  mark  consisting  of  two  parallel 
red  lines. 
Article  17 
Where  there  is  no  outer  packing,  all  the 
particulars which in pursuance of the fore-
going  articles  should  appear  on  that pack-
ing  shall be  given  on the  container. 
Article  18 
The particulars  stipulated  in  paragraphs  6, 
7  and  8  of Article  13  must be  printed on 
the  outer  packing  and  on the  container in 
the  language  or  languages  of  the  country 
in  which  the  pharmaceutical  products  are 
offered  for  sale. 
Article  19 
Nothing  in  the  chapter  shall  prevent  the 
publication  on  the  other  packing  of  other 
particulars  required  by  regulation  and  not 
explicitly  referred  to  in  this  directive. 
Article  20 
If the provisions of the present chapter are 
not  observed,  and  an  order  addressed  to 
the person concerned has been ignored, the 
authorities of the  Member States  may  sus-
pend  or withdraw  the  licence. 
Any decision  taken under the  terms  of the 
foregoing  paragraph must state the grounds 
therefor.  The  person  concerned  shall  be 
notified thereof and shall  also be  informed 
of remedies open to him at law and of the 
time-limit  within  which  an  appeal  may  be 
lodged. 
CHAPTER V 
Arrangements  for  application 
and  transitional  measures 
Article  21 
A  licence  may  not be  withheld,  suspended 
or  withdrawn  except  for  the  reasons  set 
forth  in  this  directive. 
Article  22 
The  Member  States  shall  put  into  effect 
any  laws,  regulations  and  administrative 
instructions  needed  to  comply  with  the 
provisions  of  the  present  directive  within 
twelve  months  of  notification  and  shall 
inform  the  Commission  forthwith  of  the 
action  taken. 
Article  23 
Regulations  made in  pursuance of the pre-
sent  directive  shall  apply  to  products 
licensed for sale by virtue of the preceding 
provisions  two  years  after  the  notification 
referred  to  in  Article  22. 
Article  24 
The  present  directive  is  addressed  to  all 
Member  States. 
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